CLOVER HEALTH INVESTMENTS, CORP. /DE

During the three months ended June 30, 2026, as described below, two of the Company’s officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K of the Securities Act).

On June 8, 2026, Conrad Wai, Chief Executive Officer of Counterpart Health, Inc., our subsidiary, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The trading arrangement was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and includes a cooling-off period of 90 days. The arrangement provides for the potential sale of up to 1,470,056 shares of the Company’s Class A Common Stock, subject to specified market price conditions and other terms, beginning no earlier than September 15, 2026, and ending no later than June 17, 2027. Mr. Wai has informed the Company that the purpose of the trading arrangement is to facilitate personal financial planning, including tax and diversification strategies. Any transactions under the arrangement will be disclosed publicly through Form 4 filings with the Securities and Exchange Commission, as applicable.

On May 14, 2026, Andrew Toy, the Chief Executive Officer of the Company and a director adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The trading arrangement was entered into during an open trading window in accordance with the Company's Insider Trading Policy and includes a cooling-off period of 90 days. The trading arrangement provides for the potential sale of up to 3,786,201 shares of the Company's Class A Common Stock, subject to specified market price conditions and other terms, beginning no earlier than August 13, 2026, and ending no later than December 31, 2027. Mr. Toy has informed the Company that the purpose of the trading arrangement is to facilitate personal financial planning, including tax and diversification strategies. Any transaction under the trading arrangement will be disclosed publicly through Form 4 filings with the SEC, as applicable.